Literature DB >> 29406497

Roche pays $1.7 billion to target tumors' genetic signatures.

.   

Abstract

Entities:  

Year:  2018        PMID: 29406497     DOI: 10.1038/nbt0218-123

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Loxo TRK inhibitor data wows oncologists.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2017-08-08       Impact factor: 54.908

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.